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Did A Rising Tide Lift All
Boats? The NIH Budget And
Pediatric Research Portfolio
Although funding for pediatric research increased from FY 1998 to FY
2003, its proportion of total NIH spending went down.
by Daniel P. Gitterman, Robert S. Greenwood, Keith C. Kocis, B. Rick
Mayes, and Aaron N. McKethan
ABSTRACT: This paper examines National Institutes of Health (NIH) pediatric research
spending in absolute terms and relative to the doubling of the NIH overall budget between
fiscal years 1998 and 2003. Pediatric spending increased by an average annual rate of
12.8 percent during the doubling period (almost on par with the NIH average annual growth
rate of 14.7 percent). However, the proportion of the total NIH budget devoted to the pediat-
ric portfolio declined from 12.3 to 11.3 percent. We offer recommendations for implement-
ing existing commitments to strengthen the pediatric research portfolio and to protect the
gains of the doubling period.
T
he allocat ion of federal dollars for the support of dependent
populations has become a major policy concern. Much of the previous at-
tention focused on the economic well-being of children and the elderly—in
particular, the declining impoverishment of the elderly and the growing poverty
among children over the past half-century.1 Trends in federal spending on both
groups, reported in absolute terms and relative to each other, show evidence of
growing intergenerational inequity, leading to increased concern about whether
the projected growth in federal spending on health programs for the elderly will
come at the expense of credible commitments to programs for children.2
With that broader debate in mind, we report on the status of the National Insti-
tutes of Health (NIH) pediatric research portfolio in absolute terms and relative
to the overall NIH budget during the doubling period (fiscal years 1998–2003).
We avoid framing NIH appropriations in terms of competition between children
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and adults for scarce biomedical research dollars. Instead, we ask whether a rising
budgetary tide lifted all boats: How has the pediatric portfolio fared in the recent
era of rapid overall NIH growth?
Congress has expressed particular interest in the status of pediatric spending
and specifically requested that NIH develop performance indicators to measure
its progress toward achieving a stronger pediatric portfolio. This paper is a sys-
tematic effort to examine the status of the pediatric portfolio during the doubling
period, when the overall NIH budget increased by an actual cumulative growth
rate of 98.3 percent (75.7 percent in inflation-adjusted terms).
We also highlight the status of the pediatric portfolio within four institutes:
National Institute of Child Health and Human Development (NICHD); National
Institute of Mental Health (NIMH); National Institute of Neurological Diseases
and Stroke (NINDS); and National Human Genome Research Institute (NHGRI).
We use these examples to illustrate the benefits of quantifying pediatric spending
to assess progress as well as the dangers of drawing conclusions about limited pe-
diatric spending without accounting for the benefits of biomedical research,
which are often spread over subpopulations in undifferentiated ways.
Pessimistic assumptions about future annual growth in federal discretionary
spending will prove important for understanding the status of the pediatric port-
folio over the next decade. The dramatic increase in pediatric spending has per-
mitted NIH to fund record levels of new research and therefore to accumulate a
sizable commitment base. We conclude with a set of recommendations for imple-
menting existing commitments to strengthen the NIH pediatric research portfo-
lio and to protect the gains of the doubling period.
Background
 Federal research efforts. Numerous federal research efforts focused on child
health during the 1990s.3 Concurrently, there was increasing congressional concern
about the “inadequate attention and resources” that NIH was devoting to pediatric
research.4 In response, NIH issued its first pediatric research report in 1996, which
contained a stated commitment “to use a variety of methods” to evaluate Institutes
and Centers’ (ICs’) progress “in achieving a strengthened portfolio in research on
children.”5 Congress also urged NIH to establish guidelines for including children in
all clinical research trials. NICHD and the American Academy of Pediatrics con-
curred, and in 1998 NIH released formal guidelines to this end.6
 Mental health. Increased attention also was focused on child and adolescent
mental health in the 1990s. Pediatric research lagged behind that in other sub-
specialties, largely because of pharmaceutical companies’ indifference to marketing
psychotropic drugs to children and concerns about the ethics of including children
in research. Childhood psychopathology emphasized psychodynamic analysis, and,
thus, biomedical and psychopharmacologic research was considered unnecessary,
potentially dangerous to children, and misguided.7
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 The Children’s Health Act. With the bipartisan Children’s Health Act (CHA)
of 2000, Congress authorized expanded research on and services for childhood and
prenatal health problems. Congress directed NICHD to plan and conduct the Na-
tional Children’s Study (NCS), and the president’s FY 2005 budget includes $12 mil-
lion for the NCS, $7.5 million to come from NICHD’s budget. Congress also estab-
lished a Pediatric Research Initiative (PRI), to increase support for pediatric
research, strengthen collaborative efforts among ICs, speed the development of pe-
diatric clinical drug trials, and invest in training pediatric researchers. Congress au-
thorized $50 million for the NIH Office of the Director (OD) to support the PRI in
FY 2001. However, because the CHA became effective after the FY 2001 appropria-
tions cycle, that fiscal year’s appropriations did not include PRI funding. In FY 2002
the OD awarded $5 million, half of the Director’s Discretionary Fund, for the ICs’ pe-
diatric proposals. Other federal developments during this period included an NIH
Inter-Institute Committee on Pediatric Research to encourage the development of
new initiatives and collaboration across ICs; an Interagency Autism Coordinating
Committee; and Autism Research Centers of Excellence.
The CHA requires NIH to report annually to Congress on the total funds that
ICs award for pediatric research. The FY 2002 and 2003 PRI report highlights ini-
tiatives and explains the research and clinical significance of collaboration and ex-
panding the pediatric portfolio with supplemental discretionary dollars.8
Measuring The Pediatric Research Portfolio
High annual NIH growth rates have been accompanied by intensified interest
in the internal allocation of funds. The selection of research program areas to be
funded remains the responsibility of NIH, based on a system of investigator-
initiated projects selected through merit-based peer review.9 Many factors are
considered, including public health needs and scientific opportunity.10 Prior ef-
forts to analyze spending focused on the flow of dollars to academic pediatric de-
partments rather than on the pediatric portfolio.11
In this study, we did not attempt to determine whether the amount of funding
that NIH awards for research on particular pediatric diseases was commensurate
with measures of the burden of disease (prevalence, incidence, use of resources
and costs, mortality, morbidity, and so forth). We also recognize that the degree of
match between funding and disease burden is sensitive to the measure being used
and that advocacy groups for specific diseases can emphasize data derived via a
variety of different methods.12 NIH has an obligation to respond to public health
needs, but calculating these needs is very difficult, and there is not always a clear
correlation between spending and outcomes.13
NIH defines pediatric research as “all categories of biomedical research (basic,
clinical, epidemiological, behavioral, prevention, treatment, diagnosis, as well as
outcomes and health services) that relate to diseases, conditions, or the health/
development of [people] up to age 21.”14 In FY 1995 the NIH Budget Office directed
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all ICs to report total funding (including grants, contracts, and intramural sup-
port) related to pediatric disease and cross-cutting research areas. The office re-
ports annual spending by disease categories and populations.
The Budget Office provided specific data on congressional appropriations by
IC for FY 1993–2004; pediatric spending by IC for FY 1993–2003; and overall esti-
mates for FY 2005 and pediatric spending estimates for FY 2004 and FY 2005. The
dollars reported for these years reflect each IC’s estimates of how much pediatric
research it is likely to fund based on overall budget increases and any new initia-
tives. The figures reported by some ICs for FY 1993 and FY 1994 are direct costs
only. The NIH OD may provide seed money or may supplement IC funding, but
the same funding is not counted in both the OD’s and the IC’s spending.
Because the “doubling period” is referred to in nominal dollars, we report
growth rates in nominal terms unless otherwise noted. For future estimates, we
calculated the estimated percentage change from FY 2004 to FY 2005 for the NIH
budget and the pediatric portfolio, and report projections based on the assump-
tion that the annual rates of change will remain constant through FY 2008.
The NIH Budget And Pediatric Portfolio, FY 1998–2003
 The budget. Congress doubled the NIH budget between FY 1998 and FY 2003
(to $27.1 billion), an extraordinary commitment to accelerate appropriations, which
over the previous four decades had doubled every ten years. NIH funding had in-
creased at an average annual rate of 9 percent between FY 1971 and FY 1998.15 In FY
1994, except for a double-digit increase for AIDS and breast cancer research, the
NIH budget was static or contracting in real dollars.16 It increased by an average an-
nual rate of 5.8 percent between FY 1993 and FY 1997. The pediatric portfolio in-
creased by an average annual rate of 4.7 percent.
 Pediatric spending. During the doubling period, NIH appropriations in-
creased at an average annual rate of 14.7 percent. Pediatric spending increased by an
average annual rate of 12.8 percent—very close to NIH’s overall average annual rate.
The most dramatic increase in pediatric spending occurred between FY 1998 and
FY 2003: a growth rate of 82.4 percent in nominal terms (61.6 percent in infla-
tion-adjusted terms) (Exhibit 1). A rising budgetary tide seems to have lifted all
boats: The pediatric portfolio increased dramatically (almost on par with the NIH
budget) during the doubling period.
In FY 2000 the pediatric portfolio’s 18 percent growth rate exceeded the NIH
rate of 14 percent. Only in FY 2003 did the pediatric growth rate (8.4 percent) fall
well below NIH’s 16.2 percent annual rate of growth. The FY 2003 shift to bio-
terrorism funding likely reduced awards to pediatric areas compared with earlier
fiscal years. In FY 2004 the two growth rates converged (Exhibit 1).
Although the data show that pediatric research enjoyed a share of the benefits
of the doubling period, the proportion of the NIH budget devoted to the pediatric
portfolio declined slightly, from 12.3 to 11.3 percent, down from 13.1 percent in
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1993. Thus, while overall and pediatric spending both increased in nominal and
real terms, the proportion devoted to pediatrics remained flat, as it has done since
FY 1993 (Exhibit 2).
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EXHIBIT 1
National Institutes Of Health (NIH) Budget And Pediatric Research Portfolio, Fiscal
Years 1993–2005
Fiscal
year
Pediatric
portfolio
($ billions)
NIH total
budget
($ billions)
Pediatric portfolio
as percent of
NIH budget
Pediatric portfolio,
annual percent
change
NIH budget,
annual percent
change
1993
1994
1995
1996
1.35
1.55
1.44
1.51
10.3
10.9
11.3
11.9
13.1
14.1
12.7
12.7
–
14.7
–7.0
5.0
–
5.9
3.3
5.6
1997
1998
1999
2000
1.60
1.68
1.90
2.25
12.7
13.6
15.6
17.8
12.6
12.3
12.2
12.6
6.1
4.8
13.2
18.0
6.8
7.1
14.5
14.0
2001
2002
2003
2004
2005
2.51
2.83
3.07
3.17
3.25
20.5
23.3
27.1
27.9
28.7
12.3
12.1
11.3
11.4
11.3
11.8
12.7
8.4
3.3
2.6
14.8
13.9
16.2
3.0
2.8
Average/percent
change (FY 1998–
2003) 2.4 19.7 12.1 82.4 (61.6)a 98.3 (75.7)a
SOURCES: NIH Budget Office: congressional appropriations (FY 1993–2004; 2005 estimate); pediatric research spending (FY
1993–2003; 2004–2005 estimates).
NOTE: FY 1998 is the base level for the doubling period.
a Figures in parentheses represent Consumer Price Index (CPI) inflation-adjusted growth rates in 2003 constant dollars.
EXHIBIT 2
National Institutes Of Health (NIH) Appropriations And Pediatric Research Portfolio, 
Billions Of Dollars, Fiscal Years 1993–2005
 Distribution of the pediatric portfolio. In FY 2004 twenty-two ICs invested
in an NIH pediatric portfolio of $3.2 billion, a major increase from the $1.7 billion
distributed across eighteen ICs in FY 1993. The portfolio was not evenly distributed
across the twenty-two ICs: Almost two-thirds was concentrated in five institutes
(Exhibit 3). With few exceptions, the leading pediatric spenders have been the same
since FY 1993. They will account for the majority ($1.8 billion) of the $3.2 billion
portfolio in FY 2004. Their pediatric spending grew at an average 82.5 percent rate
(on par with the pediatric portfolio 82.4 percent rate).
Pediatric ‘High’ And ‘Low’ Spenders
Here we report on the status of pediatric research within two “leading” ICs (as
a percentage of total NIH pediatric spending) to explore how the portfolio has
fared within individual ICs and in comparison with others (Exhibit 4). NICHD
sponsors the most pediatric research; it awarded $821.1 million in FY 2004. During
the doubling period, its budget grew by 78.7 percent, while pediatric spending
within NICHD grew by 74.1 percent. While the NIH budget more than doubled,
NICHD, the lead pediatric IC, experienced a smaller rate of growth (Exhibit 5).
 High spenders. NICHD. In FY 2004, 66.1 percent of NICHD’s budget was
awarded to pediatric research, by far the highest proportion of all ICs. NICHD’s
portfolio excludes all reproductive, behavioral, demographic, and rehabilitation re-
search not specifically aimed at pediatric populations. While it is often viewed as
the institute for the “profession of pediatric research,” NICHD accounted for only a
quarter of the NIH pediatric portfolio in FY 2004 (Exhibit 3). Thus, the majority of
pediatric dollars are awarded by other ICs. In addition, while pediatric spending has
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EXHIBIT 3
National Institutes Of Health (NIH) Pediatric Portfolio, By Top Ten Institute Pediatric 
Spenders (As Percentage Of Total), Fiscal Year 2004
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EXHIBIT 4
Selected National Institutes Of Health (NIH) Institute Budgets And Pediatric
Portfolios, Millions Of Dollars, Fiscal Years 1993–2005
Fiscal
year
NIH ($) NICHD ($) NIMH ($) NINDS ($) NHGRI ($)
Ped. Total Ped. Total Ped. Total Ped. Total Ped. Total
1993
1994
1995
1996
1,349
1,547
1,439
1,512
10,327
10,938
11,300
11,928
528
552
391
408
528
555
512
593
53
150
169
188
584
613
542
660
68
89
86
86
600
631
627
684
0
10
15
15
106
127
152
169
1997
1998
1999
2000
1,604
1,681
1,903
2,245
12,741
13,648
15,629
17,821
425
453
506
587
632
672
750
858
192
197
237
286
701
750
861
973
98
105
109
65
729
781
903
1,029
14
16
14
15
189
218
265
336
2001
2002
2003
2004
2005
2,510
2,829
3,066
3,168
3,251
20,458
23,296
27,067
27,888
28,677
664
734
790
821
846
976
1,112
1,206
479
1,281
336
388
405
417
429
1,106
1,247
1,341
613
1,421
81
119
142
145
147
1,176
1,327
1,456
631
1,546
16
20
25
25
26
382
429
465
479
493
Percent
change (FY
1998–2003) 82.4% 98.3% 74.1% 78.7% 105.8% 78.7% 35.6% 86.6% 54.1% 113.6%
SOURCES: NIH Budget Office: congressional appropriations (FY 1993–2004; 2005 estimate); pediatric research spending (FY
1993–2003; 2004–2005 estimates).
NOTES: All figures and growth rates are reported in nominal dollars. FY 1998 is the base level for the doubling period. Prior to
FY 1995, the National Institute for Child Health and Human Development (NICHD) reported its total appropriation as “funding
for children.” After FY 1995, NICHD narrowed its criteria to exclude research not aimed at improving the health of pediatric
populations. The National Institute of Mental Health (NIMH) reported that prior to FY 1995 it had not included intramural
research and contracts in the budget data. NINDS is National Institute of Neurological Diseases and Stroke. NHGRI is the
National Human Genome Research Institute.
EXHIBIT 5
National Institutes Of Health (NIH) And Pediatric Growth Rates By Selected Institutes, 
Fiscal Years 1993–2005
increased, NICHD’s proportion of the pediatric portfolio has remained relatively flat
at 26 percent.
Historically, a small percentage of NIH funding has flowed to pediatric depart-
ments. NICHD, as directed by the CHA in 2000, has increased the number and
size of research training grants to institutions supporting pediatric training and
career development awards to individuals in pediatric clinical and basic research.
In FY 2003 NICHD supported $17.6 million ($2.1 million more than in FY 2002) in
funding through fellowships, career awards, training grants, and the Child Health
Research Centers (CHRCs).
NIMH. NIMH, the second leading pediatric spender, accounted for 13.2 percent
of the portfolio in FY 2004. During the doubling period, the NIMH budget in-
creased by a rate of 78.7 percent. Its pediatric spending grew 105.8 percent (com-
pared with the NIH pediatric portfolio rate of 82.4 percent). NIMH is one of a few
ICs whose pediatric spending growth rate well exceeded the institute’s overall
rate during the doubling period (Exhibit 5). Much of the newly committed funding
went to studies of depression and anxiety in children and adolescents. It is difficult
to determine whether this sizable increase is the result of a growing incidence of
children’s mental disorders or a contributor to their identification and diagnosis.
 Low spenders. NINDS and NHGRI offer examples of ICs with pediatric
spending that is below the NIH average (defined as a percentage of the NIH pediat-
ric portfolio). However, data from each illustrate the complexities of quantifying pe-
diatric spending as well as the danger of drawing inappropriate inferences about the
implications of such spending for the status of their portfolios.
NINDS. NINDS had one of the largest overall budget increases during the dou-
bling period, 86.6 percent. In part, this reflects advances in the understanding of
neurological diseases and recognition of their strong impact on families. However,
NINDS’ pediatric spending experienced more modest growth of 35.6 percent—
less than half the ICs’ rate (Exhibit 5). The proportion of the NINDS budget
awarded to pediatrics decreased from 11.3 percent to 9.7 percent between FY 1993
and FY 2003. NINDS has fallen in the rankings from sixth (in 2000) to ninth (in
2003) in terms of the percentage of its budget awarded to pediatric research.
Why has NINDS’ pediatric spending fallen if, like other ICs, it makes no alloca-
tion of funds by subpopulation? Some of the decrease could represent a problem
with labeling what research is relevant to pediatric neurological diseases. Other
changes have also played a role. The number of child neurologists has been stag-
nant during the past decade, while the demand for clinical services has ballooned.
NINDS is attempting to encourage more child neurologists to choose research ca-
reers by funding the K–12 Neurological Sciences Academic Development Award.
The effectiveness of this program remains unknown.
In addition, clinical studies of children usually require multicenter collabora-
tion. NINDS and professional child neurology organizations have not been able to
organize many collaborative efforts. NINDS has sponsored workshops to help in-
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vestigators develop directions for collaborative research, but the resulting recom-
mendations have led to projects only infrequently. For example, the NINDS
Workshop/Report on Perinatal and Childhood Stroke recommended a multi-
disciplinary collaborative effort. Although professionals have met to plan re-
search, no funded collaborative studies are forthcoming. Many studies of chil-
dren’s neurological diseases have been organized under the sponsorship of the
pharmaceutical industry, especially when this was required by the Food and Drug
Administration (FDA). These trends have resulted in fewer investigators and stud-
ies that bring advances in basic science to children with neurological diseases.
NHGRI. NHGRI represents a case where quantification of pediatric spending
can underestimate the impact of biomedical research that is not specifically re-
ported as part of the official pediatric portfolio. For example, NHGRI spent $25.3
million on pediatric research in FY 2004, just 5.3 percent of its budget. NHGRI’s
budget more than doubled (113.6 percent) and its pediatric spending increased by
54 percent during the doubling period (Exhibit 5). However, NHGRI’s research
has implications for pediatric populations, although it is not counted as pediatric
spending per se. As opposed to other ICs, NHGRI provides resources for biomedi-
cal research with a broad array of applications, such as the effort to map the hu-
man genome sequence. This is typical of much of what NHGRI does, including
such initiatives as the Encyclopedia of DNA Elements (ENCODE) and the
Haplotype map (HapMap). This “nonpediatric” research will have important im-
plications for advancing knowledge of childhood disorders.17
Caveats On Interpreting Spending Trends
 Diffuse research categories. In drawing inferences from aggregate research
spending patterns, we note that there is always a challenge in determining the “ap-
propriate” amount of spending on a particular subpopulation or disease. In addition,
more and more biomedical research has implications that can be generalized across
diseases, organs, and age groups, and this can frustrate any true effort to “count”
them under any single disease or subpopulation biomedical research category.
 Clinical research. The data reported include NIH support for research in de-
velopmental biology and clinical pediatrics. Thus, developmental biology alone
could account for the steady growth rate of the pediatric portfolio. Although this
work may lead to new insights into the pathophysiology of diseases that affect chil-
dren, and hence to new ways to diagnose and treat them, many clinical researchers
remain concerned that we are not applying what we already know. Also, the lack of
integration of research efforts into centers where basic and clinical scientists re-
search and care for children with complex medical needs compounds the difficulty
of performing high-quality, outcomes-based clinical and basic science research.
 Bioterrorism spending. Bioterrorism took a big share of NIH appropriation
growth in the final years of the doubling period, and the shares of the overall in-
crease going to pediatric-related research areas have likely dropped off. For example,
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NIH reported a 536 percent increase in bioterrorism spending between FY 2002 and
the FY 2005 request. There is concern that the continuing increases in biological de-
fense funding may “crowd out” spending for pediatric areas.
 Erosion of doubling-era gains. Finally, many biomedical researchers fear that
future annual levels of growth below 6–8 percent may erode the gains NIH achieved
during the doubling period. Between FY 2004 and FY 2005, NIH appropriations are
projected to increase by 2.8 percent, while pediatric spending is projected to grow
by 2.6 percent. According to the FY 2004–2008 Biomedical Research and Develop-
ment Price Index (BRDPI) estimates, the NIH budget would need to grow by at
least 3.5–3.8 percent just to keep pace with inflation (Exhibit 6). These are far from
double-digit increases and might not be enough to maintain the commitments of the
doubling era.
The Future Of The Pediatric Portfolio, FY 2005–2010
The recent growth of the NIH budget and its pediatric portfolio has permitted
ICs to fund record levels of research and therefore to accumulate a substantial
commitment base. The challenge for NIH will be to balance current commit-
ments, new projects, and funding of new investigators. Management of that base
will make NIH vulnerable if funding levels remain static. To protect the gains
achieved and to capitalize on recent commitments to strengthen the pediatric
portfolio, we recommend the following.
 Fund NIH to exceed biomedical inflation. Congress appropriated a 3.7 per-
cent increase to NIH in FY 2004. The president’s FY 2005 budget proposed a 2.6
percent increase.18 Most of the twenty-seven ICs would receive increases in the
2.8–3.0 percent range, and NICHD would receive a 3.1 percent increase. Biomedical
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EXHIBIT 6
Annual Growth Rates Of National Institutes Of Health (NIH) And Pediatric Portfolio, 
Relative To Biomedical Inflation (The BRDPI), Fiscal Years 1993–2008
research inflation tends to exceed the Consumer Price Index (CPI) by approxi-
mately 1.5 percent per year. Unless Congress provides annual increases that well ex-
ceed the BRDPI rates, NIH and the pediatric-specific commitments it made during
the doubling period will become increasingly vulnerable.
 Fund the PRI with specific appropriations. The main purpose of the PRI was
to increase existing support for pediatric research. While Congress authorized $50
million to support the PRI in FY 2001 and “such sums as may be necessary” for FY
2002–2005, to date there have been no specific PRI appropriations. According to a
key staffer, Congress never intended to make earmarked appropriations, consistent
with its usual practice of funding ICs but not disease areas or subpopulations. Ac-
cordingly, it was expected that NIH would allocate dollars from within its overall
budget to fund research consistent with the PRI. If the PRI is to be supported with
dedicated dollars that represent new funding, supplemental appropriations are the
only mechanism by which the pediatric portfolio can expand beyond its “fixed” slice
of the budgetary pie.
 Support the NIH child inclusion policy and report on its performance.
With a static proportion of funding awarded to pediatric research, including chil-
dren in all relevant clinical research will become increasingly important. There has
never been any effort to evaluate the impact of or develop performance indicators for
NIH’s child inclusion policy. Because children are counted in numbers of research
subjects along with adults, retrospective evaluation may be difficult. It is important,
if only prospectively, to know whether the NIH guidelines can be effective and to
recommend ways to strengthen the inclusion of children in future research.
 Examine and evaluate the NCS’s budgetary trade-offs. NICHD’s FY 2005
budget request includes planning dollars for the National Children’s Study (NCS)
but not funding to launch it. Congress has yet to allocate any specific additional ap-
propriations for study implementation. Excluding expenditures for analysis and re-
porting, estimated total implementation costs are approximately $2.3 billion (not
adjusted for inflation). For recruitment and follow-up during pregnancy and in-
fancy, costs increase to a maximum of $151 million in 2007, then decrease to approxi-
mately $93 million per year from 2010 to completion in 2028.19 In the current era of
tight budgets, it is inevitable that internal funding designated for the study would
take money away from other program research areas. Without additional appropria-
tions or nongovernmental support, it is highly unlikely that NICHD, as the lead
agency, can move beyond the planning stage.
 Broaden the life-cycle focus of pediatric research. The tendency to define
all economic and health well-being issues as distributional problems among age
groups at a slice in time must be avoided. The pediatric community needs to empha-
size the potential for investments in pediatric research to influence health and hu-
man development across the life cycle. For example, a more complete understanding
of the plasticity of the brain might contribute to methods for educating children and
preserving cognitive function throughout life. Also, an understanding of the rela-
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tionship between genetic variation and disease risk promises to change greatly the
prevention and treatment of childhood and adult illnesses. Pediatricians and advo-
cacy groups will need to form partnerships with their adult-focused research and
policy colleagues and offer new conceptual arguments (and evidence) about the lon-
ger-term benefits of today’s investment in the health and well-being of our children.
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